Clay Siegall Promotes ADCETRIS for Cancer Treatment


For centuries now, cancer has been a universal medical problem. According to medical reports, most cancers are untraceable at an early age. That is why over 10,000 people lost their lives to the life-threatening disease annually. Following that report, many scientists and researchers have made finding modern treatment and therapy for cancer their core objective at work. One such scientist and physician is Clay Siegall. In 1998, he co-founded Seattle Genetics. Since then, he has been president, chief executive officer and chairman of the company. Under Clay’s leadership, Seattle Genetics has developed distinct channels of antibody piped cancer therapies with ADCETRIS being the most instrumental and recent element in therapies. The brentuximab vedotin was allowed into the U.S markets in 2011.


In October 2016, Clay Siegall announced Seattle Genetics’ new move towards a revolutionary broadening of employing a new drug. In an interview with Cooper Daniels, a news commentary, Clays said that ADCETRIS was a new drug in the market and hopefully, it would play an instrumental role in fighting cancer. The mechanism behind ADCETRIS was being tested in over seventy cancer research institutions. The drug was majorly introduced for lymphoma treatment. ADCETRIS is widely applied in the treatment of lymphoma. The drug took up to $226 million in the United States of America. According to reports, the trades added up to $225 million in nations. This data was in accordance to the director of investors.

Roles of Modern Therapy

Clay Siegall plays a key role in Seattle Genetics. Through Clay’s leadership and guidance, the company has been for a long time focusing on developing and commercializing revolutionary, empowered and proven antibody-based therapies for cancer treatment. Seattle Genetics is the lead the world in making antibody-drug conjugates. This is a modern technology tailored to curb the targeting ability of harmful antibodies that contribute to the growth of cancer. These antibodies work by sparing non-targeted cells. The result is reduced toxic effects during conventional chemotherapy. This ensures the enhancement of antitumor activities.

About Clay Siegall

Clay Siegall has been an active participant in developing cancer therapies for treatment at Seattle Genetics. He is the president of the company. He attended the University of George Washington for his PhD and majored in Zoology at the University of Maryland.